General
Preferred name
TOFOGLIFLOZIN
Synonyms
CSG-452 hydrate ()
TOFOGLIFLOZIN HYDRATE ()
Tofogliflozin (hydrate) ()
Tofogliflozin(CSG 452) ()
Tofogliflozin ()
CSG452 ()
CSG 452 ()
Tofogliflozin monohydrate ()
R-7201 ()
Tofogliflozin hydrate ()
RO4998452 ()
RO-4998452 ()
CSG-452 ()
P&D ID
PD071921
CAS
1201913-82-7
903565-83-3
Tags
drug candidate
natural product
drug
available
Approved by
PMDA
First approval
2014
Drug Status
investigational
approved
Max Phase
Phase 3
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Tofogliflozin is a selective sodium/glucose cotransporter 2 (SGLT2; SLC5A2) inhibitor (a 'gliflozin' family drug ) developed as a treatment for type 2 diabetes. We show the anhydrous structure as represented in the INN record for tofogliflozin. In practice the drug is administered as the monohydrate (PubChem CID 46908928).
Tofogliflozin has favourable oral bioavailability and pharmacokinetic profile . (GtoPdb)
Compound Sets
13
Cayman Chemical Bioactives
23509
ChEMBL Drugs
CHEMBL2110731
CHEMBL2105711
Drug Repurposing Hub
DrugBank
DB11824
DrugCentral
4892
DrugCentral Approved Drugs
4892
EU-OPENSCREEN Bioactive Compound Library
EOS100802
Guide to Pharmacology
9395
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL2110731
MedChem Express Bioactive Compound Library
HY-13413
ReFrame library
Selleckchem Bioactive Compound Library
tofogliflozin-csg-452
TargetMol Bioactive Compound Library
T5016
External IDs
34
Properties
(calculated by RDKit )
Molecular Weight
386.17
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
4
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
2
cLogP
1.0
TPSA
99.38
Fraction CSP3
0.45
Chiral centers
5.0
Largest ring
6.0
QED
0.63
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Immunology/Inflammation
NF-¦ÊB
Membrane Transporter/Ion Channel
Metabolic Enzyme/Protease
NF-κB
Target
SGLT2
ROS
GCK
Reactive Oxygen Species
SGLT
Indication
diabetes mellitus
MOA
sodium/glucose cotransporter inhibitor
Source data